Search clinical trials for: Bevacizumab Pemetrexed

Total 3433 results

Swiss Group for Clinical Cancer Research

Completed

Bevacizumab, Pemetrexed Disodium, and Cisplatin or Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Non-Small Cell Lung Cancer. A Multicenter Phase II Trial Including Biopsy at Progression (BIO-PRO Trial).

Lung Cancer

Switzerland
H. Lee Moffitt Cancer Center and Research Institute
Genentech, Inc.

Terminated

Carboplatin, Bevacizumab and Pemetrexed in the First-Line Treatment of Patients With Malignant Pleural Mesothelioma (MPM)

Mesothelioma

United States
PD Dr. med. Wolfgang Schuette
Eli Lilly and Company; Roche Pharma AG

Completed

Efficacy Study of Avastin® With Pemetrexed +/- Carboplatin to Treat Elderly Patients With Non-small Cell Lung Cancer (65plus)

Non-squamous Non-small Cell Lung Cancer

Germany
Si-Yu Wang

Completed

Neoadjuvant Pemetrexed, Carboplatin and Bevacizumab in Unresectable, Locally Advanced Lung Adenocarcinoma

Lung Cancer

China
Northwestern University
National Cancer Institute (NCI)

Completed

Carboplatin, Pemetrexed Disodium, and Bevacizumab in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

Lung Cancer

United States
Sun Yat-sen University

Unknown

Pemetrexed/Cisplatin With or Without Bevacizumab in Brain Metastases From Non Squamous Non-small Cell Lung Cancer

Bevacizumab | Brain Metastases | Non Squamous Non-small Cell Lung Cancer

China
Accelerated Community Oncology Research Network
Eli Lilly and Company; Genentech, Inc.

Completed

Phase II Study Alimta and Gemzar + Avastin as First Line Chemotherapy for Elderly Patients With Stage IIIB/IV NSCLC

Non-Small Cell Lung Cancer

United States
Intergroupe Francophone de Cancerologie Thoracique
University Hospital, Caen; Groupe Français de Pneumo-Cancérologie

Completed

Mesothelioma Avastin Plus Pemetrexed-cisplatin Study (MAPS)

Mesothelioma

France
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Not yet recruiting

A Study of SHR-1701 Plus Bevacizumab and Chemotherapy in Non-Small-Cell-Lung-Cancer

Advanced or Metastatic Non-squamous Non-small-cell Lung Cancer
Sun Yat-sen University
GeneCast Biotechnology Co., Ltd.; Allist Pharmaceuticals, Inc.

Recruiting

Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA (FOCUS-C)

Non-small Cell Lung Cancer

China
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Pemetrexed Disodium and Bevacizumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Lung Cancer

United States
Hoffmann-La Roche

Completed

AVAPERL1 Study: A Study of Avastin (Bevacizumab) With or Without Pemetrexed as Maintenance Therapy After Avastin in First Line in Patients With Non-Squamous Non-Small Cell Lung Cancer

Non-Squamous Non-Small Cell Lung Cancer

France, Germany, Spain, Sweden, Russian Federation, Greece, Switzerland, Korea, Republic of, Italy, Netherlands, Turkey, United Arab Emirates
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Pemetrexed, Carboplatin, and Bevacizumab as First-Line Therapy in Treating Older Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Lung Cancer

United States
Columbia University

Terminated

A Study of Cisplatin + Pemetrexed + Avastin as First-Line Therapy in Patients With Advanced Non-Small Cell Lung Carcinoma (NSCLC)

Non-Small Cell Lung Cancer

United States
Veeda Oncology
Eli Lilly and Company; Sanofi; Genentech, Inc.

Completed

A Phase II Study of Eloxatin and Alimta in Combination With Bevacizumab in Advanced Non-Squamous NSCLC

Non-Small Cell Lung Cancer

United States
The First Affiliated Hospital of Guangzhou Medical...

Unknown

Pemetrexed Plus Oxaliplatin as Adjuvant Chemotherapy for Radically Resected Non-Small Cell Lung Cancer

Non Small Cell Lung Cancer

China
Kobe City General Hospital

Terminated

The Safety and Efficacy of Pemetrexed Rechallenge With Bevacizumab

Advanced Non-small Cell Lung Cancer

Japan
Sun Yat-sen University

Recruiting

Study of Cadonilimab Combined With Bevacizumab and Standard Chemotherapy as First Line Therapy in Unresectable Pleural Mesothelioma

Pleural Mesothelioma

China
Centre Francois Baclesse
GFPC

Recruiting

A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies (GFPC 06-2018)

ALK Gene Rearrangement Positive | NSCLC Stage IV | NSCLC Stage IIIB | EGFR Gene Mutation | ROS1 Gene Mutation

France
Armando Santoro, MD

Completed

Phase II Study of Bevacizumab, Pemetrexed and Carboplatin as First-Line Therapy in Malignant Pleural Mesothelioma

Mesothelioma

Italy
University of Texas Southwestern Medical Center
University of Chicago; Columbia University; Duke University

Completed

Cisplatin, Pemetrexed and Bevacizumab for Untreated Malignant Mesothelioma

Mesothelioma

United States
Shanghai Cancer Hospital, China

Unknown

Efficacy and Safety of Platinum-based Chemotherapy + Bevacizumab + Durvalumab, and Salvage SBRT for IV Non-Small Cell Lung Cancer Patients With EGFR Mutations After Failure of First Line Osimertinib: A Multicenter, Prospective, Phase II Clinical Study

Lung Cancer Stage IV，EGFR-mutant，TKI，PD-L1，SBRT

China
Sichuan Cancer Hospital and Research Institute

Not yet recruiting

Tislelizumab +Bevacizumab+pc for Untreated EGFR+ and High PD-L1 Non-squamous NSCLC

Non-squamous Non-small Cell Lung Cancer | EGFR Gene Mutation

China
Eli Lilly and Company
Genentech, Inc.

Completed

Study of Pemetrexed + Carboplatin + Bevacizumab + Enzastaurin Versus Pemetrexed + Carboplatin + Bevacizumab + Placebo in Participants With Non-Small Cell Lung Cancer Who Have Not Been Previously Treated With Chemotherapy

Non-small Cell Lung Cancer

United States
Christiana Care Health Services
Eli Lilly and Company

Completed

Carboplatin, Bevacizumab and Pemetrexed in Advanced Non Small Cell Lung Cancer (H3E-US-X072)

Non Small Cell Lung Cancer
Hunan Province Tumor Hospital

Recruiting

Pembrolizumab Plus Bevacizumab and Chemotherapy for ALK-rearranged NSCLC With Persistent 5'ALK (BEYOND)

Lung Adenocarcinoma | ALK Gene Mutation | Immunotherapy

China
UNC Lineberger Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Carboplatin, Pemetrexed Disodium, and Bevacizumab for Patients With Stage III or IV Non-Small Cell Lung Cancer Who Are Light/Never Smokers

Lung Cancer

United States
Patrick Joseph Loehrer Sr.

Completed

Phase II Study of Alimta (Pemetrexed) Treatment of Advanced Thymoma and Thymic Carcinoma

Thymic Carcinoma | Thymoma

United States
Genentech, Inc.

Completed

A Study of the Safety and Pharmacology Of PI3-Kinase Inhibitor GDC-0941 In Combination With Either Paclitaxel And Carboplatin (With or Without Bevacizumab) or Pemetrexed, Cisplatin, And Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer

Non-Squamous Non-Small Cell Lung Cancer

United States, France, Netherlands
Gruppo Oncologico Italia Meridionale

Unknown

Quality of Life Comparison in Advanced Non-squamous Non Small Cell Lung Cancer (ERACLE)

Non-squamous Nonsmall Cell Neoplasm of Lung

Italy
University of Chicago
Genentech, Inc.

Completed

Dose Escalation of Bevacizumab With Ambulatory Blood Pressure Monitoring in Patients With Advanced Non-squamous NSCLC (AVF4759)

Advanced Non-squamous Non-Small Cell Lung Cancer

United States
Cancer Institute and Hospital, Chinese Academy...

Unknown

Low -Dose-bevacizumab and Pemetrexed Versus TPC in Metastatic HER2-negative Breast Cancer Patients

Metastatic Breast Cancer

China
Genentech, Inc.

Completed

A Study of the Safety and Pharmacology of GDC-0980 in Combination With Either Paclitaxel and Carboplatin (With or Without Bevacizumab) or Pemetrexed and Cisplatin in Patients With Solid Tumors

Solid Cancers

United States, Spain
Genentech, Inc.

Completed

A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab (Avastin) Plus Platinum And Paclitaxel or With Pemetrexed Plus Platinum in Patients With Non-Squamous Non-Small Cell Lung Cancer

Non-Squamous Non-Small Cell Lung Cancer

Spain, France, United States, Taiwan, United Kingdom, Philippines, Latvia, Italy, Israel, Argentina, Mexico, Germany, Malaysia
Qingdao Central Hospital

Recruiting

Chemotherapy Combines With Bevacizumab and PD-1 Inhibitor in Non-squamous NSCLC

PFS | OS

China
M.D. Anderson Cancer Center

Active, not recruiting

Ensartinib, Carboplatin, Pemetrexed and Bevacizumab for the Treatment of Stage IIIC or IV or Recurrent ALK-Positive Non-small Cell Lung Cancer

Metastatic Lung Non-Small Cell Carcinoma | Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage IIIC Lung Cancer AJCC v8 | Recurrent Lung Non-Small Cell Carcinoma

United States
Qianfoshan Hospital

Recruiting

First-Line Treatment for Advanced Non-squamous Non-Small-Cell Lung Cancer With Negative Driver Gene: a Single-center, Single-Arm Trial (SPBPDC)

Advanced Non-squamous Non-Small-Cell Lung Cancer

China
Qingdao Central Hospital

Recruiting

Osimertinib Combined With Bevacizumab in Patients With Brain Metastasis Epidermal Growth Factor Receptor (EGFR) Mutation Positive Metastatic Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

China
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Terminated

Pemetrexed Disodium, Gemcitabine, and Bevacizumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Lung Cancer

United States
Hunan Province Tumor Hospital

Recruiting

Efficacy and Biomarker Development for Lung Cancer Treated With Immune Checkpoint Inhibitors (BECOME)

Lung Cancer

China
Boehringer Ingelheim

Terminated

BIBF 1120 in Combination With Pemetrexed in Advanced Non Small Cell Lung Cancer (NSCLC)

Carcinoma, Non-Small-Cell Lung

Japan
Caicun Zhou

Unknown

Gefitinib Combined With Chemotherapy or Antiangiogensis in Patients With Bim Deletion or Low EGFR Mutation Abundance

Non-small-cell Lung Cancer

China
Sun Yat-sen University

Recruiting

Neoadjuvant IBI308, Bevacizumab, Plus Pemetrexed and Carboplatin Followed by Surgery in Unresectable Stage III NSCLC (NIBCUN)

Lung Cancer Stage III

China
University of Pittsburgh
Eli Lilly and Company; Genentech, Inc.

Completed

Study of Pemetrexed and Bevacizumab in Patients With Head and Neck Cancer

Cancer

United States
Rongjie Tao
National Natural Science Foundation of China

Unknown

High-dose Pemetrexed to Treat Lung Adenocarcinoma With Brain Metastases

Brain Metastases

China
Hunan Province Tumor Hospital
Hunan Cancer Hospital

Recruiting

Efficacy and Resistance Mechanisms of IP in NSCLC With Leptomeningeal Metastases (EPIC)

Non-Small Cell Lung Cancer

China
Northwestern University
National Cancer Institute (NCI)

Unknown

Pemetrexed Disodium in Treating Patients With Recurrent Malignant Gliomas, Primary CNS Lymphoma, or Brain Metastases

Lymphoma | Brain and Central Nervous System Tumors | Metastatic Cancer

United States
Henan Cancer Hospital

Recruiting

Serplulimab Plus Bevacizumab and Chemotherapy for EGFR-mutant Metastatic NSCLC Patients After EGFR-TKI Treatment Failure

Non-Squamous Non-Small Cell Lung Cancer

China
National Cancer Institute (NCI)

Active, not recruiting

TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Serous Cystadenocarcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Recurrent... and other conditions

United States
Eli Lilly and Company

Completed

A Study of Home Administration of Pemetrexed as Maintenance Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer Metastatic | Nonsquamous Non-Small Cell Neoplasm of Lung | Non-Small Cell Lung Cancer Stage IIIB

United Kingdom, Sweden

3

Subscribe